X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
X-Chem will screen its unique DNA-encoded libraries against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: X-Chem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 05, 2023
Details:
Sironax plans to use the proceeds to support the ongoing clinical development of its portfolio of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors in addition to the continued expansion of its R&D footprint and pipeline including SIR0365.
Lead Product(s): SIR0365
Therapeutic Area: Infections and Infectious Diseases Product Name: SIR0365
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gaorong Capital
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
